ScripVenture capital investment in the biopharmaceutical industry is on an undeniable upswing, with two quarters in a row of fundraising in 2024 that outpace the activity seen in 2023, according to data fr
ScripA New York City start-up backed by big investors and led by an experienced management team is looking to break into the obesity and metabolic disease space. The company, called Metsera, Inc., was publ
ScripApril began with a flurry of new venture capital mega-rounds of $100m or more – a $160.5m series C round for Obsidian Therapeutics, Inc. , a $132m series B for Alterome Therapeutics, Inc. and a $12
ScripNovartis Reports First After Recent Storms When Novartis AG reported its second-quarter financial results, it opened earnings season for life science companies, pipping Johnson & Johnson by two da